李氏大药厂(00950)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00950 李氏大药厂

交易中 11-12 10:00:55

1.075

-0.015

-1.38%

最高1.090	最低1.070	成交量1.40万
今开1.075	昨收1.090	日振幅1.83%
总市值6.33亿	流通市值6.33亿	总股本5.89亿
成交额1.50万	换手率0.00%	流通股本5.89亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00950","market":"HK","secType":"STK","nameCN":"李氏大药厂","latestPrice":1.075,"timestamp":1794447675487,"preClose":1.09,"halted":0,"volume":14000,"delay":0,"changeRate":-0.01376146788990837,"floatShares":588835343,"shares":589000000,"eps":0.1561,"marketStatus":"交易中","change":-0.015,"latestTime":"11-12 10:00:55","open":1.075,"high":1.09,"low":1.07,"amount":15020,"amplitude":0.018349,"askPrice":1.09,"askSize":5000,"bidPrice":1.075,"bidSize":36000,"shortable":0,"etf":0,"ttmEps":0.203306,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1794456000000},"marketStatusCode":2,"adr":0,"listingDate":1026662400000,"exchange":"SEHK","adjPreClose":1.09,"dividendRate":0.053953,"openAndCloseTimeList":[[1794447000000,1794456000000],[1794459600000,1794470400000]],"volumeRatio":0.629359,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00950","defaultTab":"news","newsList":[{"id":"2682399581","title":"李氏大药厂(00950.HK)11月10日斥资3.56万港元回购3.3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2682399581","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682399581?lang=zh_cn&edition=full","pubTime":"2026-11-10 19:07","pubTimestamp":1794308864,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","00950","06622","BK1574","BK1587","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182736632","title":"李氏大药厂回购33,000股股份，涉资约3.56万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182736632","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182736632?lang=zh_cn&edition=full","pubTime":"2026-11-10 19:07","pubTimestamp":1794308841,"startTime":"0","endTime":"0","summary":"2026年11月10日，李氏大药厂公告最新翌日披露报表。公司于当日在香港联交所场内回购33,000股普通股，每股回购价为1.08港元，合计支付35,640港元。目前公司已发行股本维持在588,835,343股。根据公告，李氏大药厂已在2026年11月5日、6日及9日分别回购5,000股、50,000股及2,000股，连同本次回购在内，公司于2026年5月21日通过的购回授权项下已累计回购股份合计90,000股，占购回授权获决议通过当日已发行股份总数的约0.0153%。公告由公司董事李小芳签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"李氏大药厂回购33,000股股份，涉资约3.56万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682935890","title":"李氏大药厂(00950)11月9日斥资2140港元回购2000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2682935890","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682935890?lang=zh_cn&edition=full","pubTime":"2026-11-10 08:02","pubTimestamp":1794268972,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂(00950)发布公告，于2026年11月9日，该公司斥资2140港元回购2000股股份，每股回购价1.07港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1520795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","BK1583","06622","00950","BK1587","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168384870","title":"李氏大药厂三日回购57,000股股份，合计耗资约6.15万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1168384870","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168384870?lang=zh_cn&edition=full","pubTime":"2026-11-10 08:01","pubTimestamp":1794268897,"startTime":"0","endTime":"0","summary":"2026年11月10日，李氏大药厂发布翌日披露报表，显示公司于2026年11月5日、6日及9日在香港联交所合计回购57,000股普通股，分别占公司已发行股本的0.0008%、0.0085%及0.0003%。本次回购价格介乎每股1.07港元至1.08港元，涉资总额约61,515港元。经上述回购后，公司已发行股本仍维持在588,835,343股，暂未因相关股份尚未注销而产生变动。公告称，本次回购行为已获得董事会正式批准，并严格依照香港联交所上市规则及相关法律法规进行。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"李氏大药厂三日回购57,000股股份，合计耗资约6.15万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106161524","title":"李氏大药厂两日合计回购5.5万股股份，涉资约5.94万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106161524","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106161524?lang=zh_cn&edition=full","pubTime":"2026-11-06 18:22","pubTimestamp":1793960546,"startTime":"0","endTime":"0","summary":"李氏大药厂于2026年11月6日发布翌日披露报表。公告显示，公司分别于2026年11月5日及11月6日，在香港联交所每股港币1.075元及1.08元的价格回购普通股5,000股及50,000股，合计回购55,000股，占当时已发行股本约0.0093%，总涉资约港币5.94万元。本次回购完成后，截至2026年11月6日，公司已发行股本维持在588,835,343股，库存股份数为0股。公告同时披露，公司于2026年5月21日获通过回购授权，可回购股份总数为58,883,534股，此次已根据该授权在联交所回购股份50,000股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"李氏大药厂两日合计回购5.5万股股份，涉资约5.94万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187139418","title":"李氏大药厂回购5,000股股份，耗资约5,375港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187139418","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187139418?lang=zh_cn&edition=full","pubTime":"2026-11-05 18:41","pubTimestamp":1793875297,"startTime":"0","endTime":"0","summary":"李氏大药厂控股有限公司（港股代码00950）于2026年11月5日公告称，当日在香港联合交易所场内回购5,000股普通股，占公司现有已发行股本约0.0008%。每股回购价格为每股1.075港元，合计耗资5,375港元。\n公司表示，回购后已发行股本总数暂时维持在588,835,343股；本次回购的股份尚未注销。根据公告，购回授权于2026年5月21日获得通过，公司可回购的股份总数为58,883,534股，这次回购是在该授权范围内进行。\n公司进一步确认已遵守上市规则及相关法律规定，回购事项经董事会正式批准。该公告由董事李小芳签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"李氏大药厂回购5,000股股份，耗资约5,375港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681236400","title":"李氏大药厂(00950)11月5日斥资5375港元回购5000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681236400","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681236400?lang=zh_cn&edition=full","pubTime":"2026-11-05 18:39","pubTimestamp":1793875195,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂(00950)发布公告，于2026年11月5日该公司斥资5375港元回购5000股，回购价格为每股1.075港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1519162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","EWH","BK1574","06622","BK1587","BK1191","00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681023623","title":"李氏大药厂(00950.HK)11月5日斥资5375港元回购5000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681023623","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681023623?lang=zh_cn&edition=full","pubTime":"2026-11-05 18:39","pubTimestamp":1793875195,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","06622","00950","BK1587","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166435154","title":"李氏大药厂发布2026年10月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1166435154","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166435154?lang=zh_cn&edition=full","pubTime":"2026-11-02 19:51","pubTimestamp":1793620294,"startTime":"0","endTime":"0","summary":"李氏大药厂控股有限公司于2026年11月2日公布了截至2026年10月31日的股份变动月报表，披露其法定股本、已发行股本以及库藏股等情况。同时，公司已发行普通股由上月底的588,835,343股保持不变，库藏股数量继续为0股。本月内未发生新增发行、购回、注销或库藏股变动，公司确认其公众持股量继续符合香港联交所相关上市规则要求。据公告披露，截至2026年10月31日，公司整体股本结构稳定，并遵循了香港联交所《上市规则》和适用法律的相关规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154419041","title":"李氏大药厂9月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1154419041","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154419041?lang=zh_cn&edition=full","pubTime":"2026-10-02 17:46","pubTimestamp":1790934372,"startTime":"0","endTime":"0","summary":"李氏大药厂控股有限公司于2026年10月2日发布2026年9月30日止月份的证券变动月报表，报告期内公司股本结构及已发行股份数量均未发生变化。公司月末实际发行股份总数与库藏股数目稳定在上述水平。根据公告，李氏大药厂控股有限公司现有两项购股权计划，分别于2012年5月10日及2022年5月19日通过并采纳，合计授出的购股权达到19,918,000股及4,778,000股。公告由董事李小芳签署。公司强调，截至9月底，公司股本结构保持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669246722","title":"董事总经理李烨妮增持李氏大药厂(00950.HK)20.6万股 每股作价1.15港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669246722","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669246722?lang=zh_cn&edition=full","pubTime":"2026-09-24 19:24","pubTimestamp":1790249060,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1574","BK1587","00950","06622","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199360647","title":"李氏大药厂2026年上半年营收7.97亿元，经调整净利润0.95亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1199360647","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199360647?lang=zh_cn&edition=full","pubTime":"2026-09-23 07:06","pubTimestamp":1790118415,"startTime":"0","endTime":"0","summary":"2026年上半年，李氏大药厂实现营收约7.97亿元，同比增长14.6%。经调整净利润约0.95亿元，较去年同期0.67亿元增长41.4%。毛利率为56.2%，比上年同期上升4.4个百分点。经营活动产生的现金流约2.35亿元，而去年同期为1.84亿元，增幅达到27.3%。报告期内，公司销售及分销费用为1.80亿元，同比增长18.3%；行政费用达1.86亿元，同比增长83.2%。研发投入方面，公司合计产生约2.04亿元，同比增长28%，其中1.53亿元计入当期费用，占营收比重从上年同期的6.0%提升至19.2%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"李氏大药厂2026年上半年营收7.97亿元，经调整净利润0.95亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156184693","title":"李氏大药厂 - 1Cbio将保留根据与FDA的IND申请协议所产生数据的使用权与访问权","url":"https://stock-news.laohu8.com/highlight/detail?id=1156184693","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156184693?lang=zh_cn&edition=full","pubTime":"2026-09-09 22:39","pubTimestamp":1788964770,"startTime":"0","endTime":"0","summary":"李氏大药厂——1Cbio将保留其依据与美国食品药品监督管理局（FDA）所签协议而生成的数据的访问及使用权。这一权利涵盖履行新药临床试验申请（IND）过程中所产生的各类数据资料。协议框架下，相关数据的获取与利用权限得以明确界定，为后续监管沟通与申报流程提供了关键支撑。值得注意的是，此类安排不仅涉及技术层面的合规要求，亦牵涉到知识产权与商业机密的保护策略。鉴于生物医药领域研发周期长、投入大且监管严苛的特点，对数据权的清晰界定于合作双方而言均是风险管控的重要环节。由此，上述权利的保留将持续为1Cbio在推进IND申报进程中提供必要的灵活性，助其应对监管环境中的动态变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169042852","title":"李氏大药厂达成合作：OC-3将在中国大陆等地用于治疗DNA修复突变癌症","url":"https://stock-news.laohu8.com/highlight/detail?id=1169042852","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169042852?lang=zh_cn&edition=full","pubTime":"2026-09-09 22:37","pubTimestamp":1788964649,"startTime":"0","endTime":"0","summary":"李氏大药厂日前宣布一项重要协议。根据该协议，OC-3这一药物将被开发用于治疗携带DNA修复突变的癌症患者。这一开发计划覆盖中国大陆及其他地区，为相关癌症治疗领域带来新的可能。\n此项合作聚焦于精准医疗方向，针对具有特定基因特征的肿瘤类型。DNA修复机制的缺陷，往往与某些癌症的发生发展密切相关，这使得OC-3有望成为一种更具针对性的治疗选择。\n值得关注的是，该药的市场布局不仅限于中国大陆，还延伸至其他区域。这一战略性的安排，或许意味着相关治疗方法有望惠及更广泛的患者群体。\n协议的达成，标志着李氏大药厂在肿瘤治疗领域的又一重要布局。随着相关研发工作的推进，OC-3的临床应用前景值得期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146207836","title":"李氏大药厂（00950）获OC-3大中华及东南亚独家开发生产与商业化权","url":"https://stock-news.laohu8.com/highlight/detail?id=1146207836","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146207836?lang=zh_cn&edition=full","pubTime":"2026-09-09 22:36","pubTimestamp":1788964578,"startTime":"0","endTime":"0","summary":"2026年9月9日，李氏大药厂控股有限公司公告，其全资子公司李氏大药厂（香港）有限公司已与美国生物科技公司1cBio, Inc. 签署独家许可协议，获取PARP1抑制剂OC-3在中国内地、香港、澳门、台湾及东南亚若干国家的开发、生产及商业化权利。根据协议，李氏香港将承担OC-3在上述地区取得监管批准所需的GLP安全性研究和生产活动，并负责药物供应生产安排。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191933369","title":"李氏大药厂8月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1191933369","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191933369?lang=zh_cn&edition=full","pubTime":"2026-09-02 18:12","pubTimestamp":1788343950,"startTime":"0","endTime":"0","summary":"李氏大药厂于2026年9月2日发布截至2026年8月31日的股份变动月报表。公告显示，公司于报告期末的注册股本为10亿股普通股，面值每股0.05港元，折合注册股本总额5000万港元，与上月保持一致。截至8月31日，公司已发行股份为588,835,343股，库藏股数量为0，合计已发行股份总数588,835,343股，均较上月无变化。上述期权在报告期内未发生行使或变动。整体来看，本月度公司股本结构未发生新增发行、股份购回或注销变动。本次公告由董事李小芳签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120675824","title":"李氏大药厂2026年上半年营收7.97亿港元，经调整净利润0.95亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120675824","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120675824?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:57","pubTimestamp":1788170256,"startTime":"0","endTime":"0","summary":"李氏大药厂公告显示，截至2026年6月30日止六个月，公司营收约7.97亿港元，同比增长14.6%。经调整净利润为0.95亿港元，同比增长41.4%。报告期内毛利达到4.47亿港元，同比增长24.3%，毛利率从上年同期的51.8%提升至56.2%。公司在心血管、女性健康、儿科、罕见病及皮肤科等主攻领域的研发投入约2.04亿港元，同比增长28.0%，其中1.53亿港元计入当期费用。公司经营活动产生的现金净额为2.35亿港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"李氏大药厂2026年上半年营收7.97亿港元，经调整净利润0.95亿港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663071315","title":"李氏大药厂(00950)公布中期业绩 拥有人应占溢利9501.4万港元 同比增长41.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663071315","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663071315?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:50","pubTimestamp":1788169857,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂 公布2026年中期业绩，收益约7.97亿港元，同比增长14.6%;公司拥有人应占溢利9501.4万港元，同比增长41.4%;每股盈利16.14港仙，每股中期股息3.5港仙。其中，引进产品的收益增加24.3%至约3.37亿港元，主要源于《菲普利》、《布累迪宁》、《曲特恪》及《芮舒延》的贡献。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489545.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00950","BK1574","BK1587","BK1583","BK1191","06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662472467","title":"港股异动 | 李氏大药厂(00950.HK)盈喜后涨超20% 预计中期股东应占纯利约8500万至9500万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662472467","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662472467?lang=zh_cn&edition=full","pubTime":"2026-08-27 10:34","pubTimestamp":1787798089,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1574","BK1191","06622","BK1587","00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662126957","title":"李氏大药厂(00950)发盈喜 预计中期股东应占纯利约8500万至9500万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662126957","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662126957?lang=zh_cn&edition=full","pubTime":"2026-08-26 21:21","pubTimestamp":1787750513,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂(00950)发布公告，集团预期截至2026年6月30日止六个月将取得未经审核股东应占纯利介于约8500万港元至9500万港元，而截至2025年6月30日止六个月则取得约6720万港元。预期集团的中期业绩有所改善，主要源于(其中包括)(i)集团的收益增长;(ii)集团的整体毛利率改善，而此乃归因于产品组合更为理想，其中利润较高之专科及引进产品占比较大，以及集团各生产基地的制造效率持续提升。上述两项因素结合产生的正面影响，足以抵销报告期内所取得研究及开发费用、销售及分销费用以及行政费用(包括与集团新综合入账的美国业务相关的成本)增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06622","BK1583","BK1574","00950","BK1587"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.leespharm.com","stockEarnings":[{"period":"1week","weight":0.014},{"period":"1month","weight":-0.0311},{"period":"3month","weight":0.0196},{"period":"6month","weight":0.0149},{"period":"1year","weight":-0.3965},{"period":"ytd","weight":-0.2457}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":0.0018},{"period":"3month","weight":-0.0425},{"period":"6month","weight":-0.0634},{"period":"1year","weight":-0.0892},{"period":"ytd","weight":-0.0513}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"李氏大药厂控股有限公司是一家主要从事药品开发、制造、市场推广及销售业务的投资控股公司。该公司通过两个分部运营业务。引进产品分部买卖引进的产品。其引进产品包括可益能注射液、菲普利口服溶液等。专利产品分部制造及销售自行研发的产品。其研发产品包括锐思力药片、ADASUVE吸入粉雾剂等。该公司药品覆盖心血管及传染疾病、皮肤医学、肿瘤学、妇科学及眼科学等领域。该公司主要在中国大陆、香港、台湾开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5625,"avgChangeRate":0.049698},{"month":2,"riseRate":0.375,"avgChangeRate":-0.022896},{"month":3,"riseRate":0.4375,"avgChangeRate":-0.02913},{"month":4,"riseRate":0.4375,"avgChangeRate":-0.000887},{"month":5,"riseRate":0.625,"avgChangeRate":0.036917},{"month":6,"riseRate":0.352941,"avgChangeRate":-0.025863},{"month":7,"riseRate":0.529412,"avgChangeRate":0.026552},{"month":8,"riseRate":0.411765,"avgChangeRate":-0.023892},{"month":9,"riseRate":0.411765,"avgChangeRate":0.012903},{"month":10,"riseRate":0.411765,"avgChangeRate":-0.014827},{"month":11,"riseRate":0.588235,"avgChangeRate":0.015429},{"month":12,"riseRate":0.4375,"avgChangeRate":0.016874}],"exchange":"SEHK","name":"李氏大药厂","nameEN":"LEE'S PHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"李氏大药厂(00950)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供李氏大药厂(00950)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"李氏大药厂,00950,李氏大药厂股票,李氏大药厂股票老虎,李氏大药厂股票老虎国际,李氏大药厂行情,李氏大药厂股票行情,李氏大药厂股价,李氏大药厂股市,李氏大药厂股票价格,李氏大药厂股票交易,李氏大药厂股票购买,李氏大药厂股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"李氏大药厂(00950)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供李氏大药厂(00950)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}